Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

dabrafenib × Other neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 67 Head & Neck 20 CNS 16 Endocrine 13 Tumor-Agnostic 11 Thoracic 10 Plasma cell 6 Other hematologic neoplasm 6 Gastrointestinal 6 Lymphoid 4 Myeloid 3 Sarcoma 2 Other solid neoplasm 2 Other neoplasm 1 Other 1 Gynecologic 1 Genitourinary 1 Classical hematology 1 Breast 1

Conditions

Rare Malignant Neoplasm 1

Interventions

Cyclophosphamide 12 fludarabine phosphate 9 Busulfan 9 Peripheral Blood Stem Cell Transplantation 8 Biopsy 8 Whole-Body Irradiation 7 Surveys and Questionnaires 7 Polymerase Chain Reaction 7 Mycophenolic Acid 7 Tacrolimus 6 Gene Expression Profiling 6 fludarabine 5 Melphalan 5 Educational Status 5 Early Intervention, Educational 5 Decitabine 5 Cyclosporine 5 Carboplatin 5 Antilymphocyte Serum 5 Aminolevulinic Acid 5 Sulindac 4 Radiotherapy 4 Patient Reported Outcome Measures 4 Microarray Analysis 4 Methotrexate 4 Methods 4 Interviews as Topic 4 Immunohistochemistry 4 Colposcopy 4 Celecoxib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡